期刊文献+

氯吡格雷对2型糖尿病合并心肌梗死患者血管再通的影响研究

下载PDF
导出
摘要 目的探讨氯吡格雷对2型糖尿病合并心肌梗死患者血管再通的影响。方法选取2013年3月—2015年6月在我院治疗的2型糖尿病合并心肌梗死患者80例,随机分为试验组和对照组各40例,对照组应用常规治疗,试验组在对照组基础上加用氯吡格雷治疗。于患者腹部皮下放置动态血糖仪感应探头,动态监测2组患者的血糖波动及记录治疗后2组患者的血管再通率。结果试验组治疗后血糖控制状况明显优于对照组,差异显著(P<0.05);试验组患者的再通率为87.5%,明显高于对照组的62.5%,差异显著(P<0.05);治疗后试验组的总有效率为92.5%,明显高于对照组的62.5%,差异显著(P<0.05)。结论 2型糖尿病合并心肌梗死应用氯吡格雷治疗可有效控制患者血糖,改善心肌梗死症状,提高血管再通率。
作者 梅锦
机构地区 南昌县人民医院
出处 《基层医学论坛》 2016年第35期4941-4942,共2页 The Medical Forum
  • 相关文献

参考文献5

二级参考文献72

  • 1Chen Z M, Jang L X, Chen Y P, et al.Addition of clopidogrel to aspirin in 45, 825 patients with acute myocardial infarction randomized placebo- eontrolled trial[J].Laneet, 2009, 36(6): 1607-1621.
  • 2Tantry US, Bonello L,Aradi D,et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding[ J]. J Am Coll Cardiol,2013,62(24 ) :2261-2273. DOI: 10. 1016/j. jacc. 2013. 07. 101.
  • 3Aradi D,Storey RF, Komócsi A,et ah Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention[ J ]. Eur Heart J, 2014,35 ( 4 ) : 209-215. DOI: 10. 1093/eurheartj/eht375.
  • 4Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing pereutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38 ) : double-blind, randomised controlled trial [ J ]. Lancel, 2009,373 (9665) : 723-731. DOI: 10. 1016/S0140-6736 ( 09 ) 60441-4.
  • 5Wallentin L, Becker RC, Budaj A, et al. Tieagrelor versus clopidogrel in patients with acute coronary syndromes [ J ]. N Engl J Med, 2009, 361 (11): 1045-1057. DOI: 10. 1056/ NEJMoa0904327.
  • 6Inker LA,Astor BC,Fox CH,et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD [ J ]. Am J Kidney Dis, 2014,63 ( 5 ) : 713- 735. DOI: 10. 1053/j. ajkd. 2014.01. 416.
  • 7Price M J, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial [ J ]. JAMA,2011,305 ( 11 ) : 1097-1105. DOI: 10. 1001/jama. 2011. 290.
  • 8Stone GW, Witzenbichler B, Weisz G, el al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study [J]. Lancet,2013,382 (9892) :614-623. DOI: 10. 1016/S0140- 6736( 13 )61170-8.
  • 9Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [ J ]. Circulation, 2011,124 ( 23 ) : 2574-2609. DOI : 10.1161/CIR. 0b013e31823a5596.
  • 10Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Pereutaneous Cardiovascular Interventions (EAPCI) [ J]. Eur Heart J,2014,35 ( 37 ) :2541-2619. DOI: 10. 1093/eurheartj/ehu278.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部